
Surein Arulananda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5094145/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1728-1732.	1.1	143
2	BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death and Disease, 2019, 10, 342.	6.3	125
3	Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. European Journal of Cancer, 2018, 105, 88-102.	2.8	53
4	Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 1588-1594.	1.1	35
5	A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. Cell Death Discovery, 2021, 7, 122.	4.7	23
6	<p>A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia</p> . Drug Design, Development and Therapy, 2020, Volume 14, 1177-1189.	4.3	21
7	BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. Cell Death Discovery, 2020, 6, 114.	4.7	13
8	Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: case report. Translational Lung Cancer Research, 2020, 9, 360-365.	2.8	13
9	The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma. Expert Review of Anticancer Therapy, 2021, 21, 413-424.	2.4	9
10	Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease. Journal of Thoracic Disease, 2019, 11, 1756-1764.	1.4	8
11	A pilot study of intrahepatic yttriumâ€90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liverâ€only metastases. Cancer Reports, 2019, 2, e1183.	1.4	7
12	Management of non-small cell lung cancer with resistance to epidermal growth factor receptor tyrosine kinase inhibitor: case discussion. Journal of Thoracic Disease, 2020, 12, 159-164.	1.4	7
13	Clinical correlates of severe thrombocytopenia from temozolomide in glioblastoma patients. Internal Medicine Journal, 2018, 48, 1206-1214.	0.8	7
14	RET â€rearranged nonâ€smallâ€cell lung cancer and therapeutic implications. Internal Medicine Journal, 2019, 49, 1541-1545.	0.8	6
15	Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non–Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: BriefÂReport. Clinical Lung Cancer, 2020, 21, e57-e60.	2.6	5
16	Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy—fortune favours the bold. Translational Lung Cancer Research, 2018, 7, S388-S392.	2.8	4
17	BRAF Mutations—A Good News Story for Immune Checkpoint Inhibitors in Oncogene-Addicted NSCLC?. Journal of Thoracic Oncology, 2018, 13, 1055-1057.	1.1	3
18	DDR Alterations as a Surrogate Marker for TMB in SCLC — Use it or Lose it?. Journal of Thoracic Oncology, 2019, 14, 1498-1500.	1.1	3

#	Article	IF	CITATIONS
19	Bronchoepidural Fistula in a Man with Actinomycosis Complicated Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1761-1762.	1.1	2
20	Pulmonary metastases: A rare manifestation of the most common cancer. Australasian Journal of Dermatology, 2013, 54, e70-e73.	0.7	1
21	The ADAM Trial. JAMA Oncology, 2017, 3, 66.	7.1	1
22	In Reply to Leone. Journal of Thoracic Oncology, 2018, 13, e22-e23.	1.1	0
23	Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC — Tarring all Patients With the Same Brush?. Journal of Thoracic Oncology, 2020, 15, 12-14.	1.1	0
24	Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer—ready for prime time?. Translational Lung Cancer Research, 2020, 9, 1728-1731.	2.8	0